Table 1.
Overall baseline characteristics and univariate comparisons based on disease activity measured by CDAI.
| n (%), mean (SD), or median (IQR) |
CDAI < 150 | p-Value | ||
|---|---|---|---|---|
| Total | CDAI ≥ 150 | (n = 99) | ||
| (n = 119) | (n = 20) | |||
| Gender, female | 67 (56.3%) | 13/20 (65%) | 54/99 (54.5%) | 0.39 |
| Age, years | 47 (15.2) | 48 (15.3) | 41 (14.2) | 0.076 |
| Age at diagnosis, years | 36.49 (14.87) | 32.3 (11.75) | 37.35 (15.34) | 0.168 |
| <16 years | 6 (5%) | 1/20 (5%) | 19/20 (95%) | 1.0 |
| 17–39 | 67 (56.3%) | 13/20 (65%) | 7/20 (35%) | 0.39 |
| ≥40 | 46 (38.7%) | 6/20 (30%) | 14/20 (70%) | 0.38 |
| Location, n (%) | ||||
| Ileal | 62 (52%) | 8/20 (40%) | 54/99 (55%) | 0.24 |
| Colonic | 15 (13%) | 2/20 (10%) | 13/99 (13%) | 1 |
| Ileocolic | 38 (32%) | 10/20 (50%) | 28/99 (28%) | 0.06 |
| Upper gastrointestinal tract | 16 (13%) | 3/20 (15%) | 13/99 (13%) | 0.73 |
| Behavior | ||||
| Non-stenosing, non-penetrating | 66 (55%) | 13/20 (65%) | 53/99 (53%) | 0.35 |
| Stenosing | 28 (24%) | 3/20 (15%) | 25/99 (25%) | 0.32 |
| Penetrating | 25 (21%) | 4/20 (20%) | 21/99 (21%) | 1 |
| Perianal disease | 28 (24%) | 8/20 (40%) | 20/99 (20%) | 0.06 |
| Therapeutic | ||||
| 5-ASA solely | 34 (28.6%) | 0 | 34/99 (34%) | 0.001 |
| Thiopurine | 48 (40.3%) | 10/20 (50%) | 38/99 (38%) | 0.33 |
| Anti-TNF-α drugs | 25 (21%) | 8/20 (40%) | 17/99 (17%) | 0.02 |
| Laboratory values | ||||
| RDW (n = 119) | 14.0 (13–15) | 14.5 (13–17) | 13 (13–14) | 0.044 |
| RDW ≥ 16 (n = 119) | 18 (15.1%) | 6/20 (30%) | 12/99 (12%) | 0.042 |
| Hgb (g/dL) (n = 119) | 12.96 (1.9) | 12.27 (1.8) | 13.11 (1.9) | 0.07 |
| Anemia (n = 119) | 35 (29.4%) | 8/20 (40%) | 27/99 (27%) | 0.26 |
| MCV (fL) (n = 117) | 89.4 (7.8) | 88.9 (9.5) | 89.56 (7.44) | 0.73 |
| PLT (uL) (n = 118) | 286200.85 (102750.04) | 298300.00 (91909.6) | 283731.63 (105087.6) | 0.57 |
| WBC (uL) (n = 119) | 7344.66 (2849.9) | 7490.35 (3636.03) | 7315.2 (2685.38) | 0.80 |
| CRP (mg/dL) (n = 60) | 1.0 (1.0–3.75) | 1.0 (0–4.75) | 1.0 (1.0–3.25) | 0.69 |
| ESR (mm) (n = 75) | 33.44 (25.82) | 33.92 (32.46) | 33.35 (24.68) | 0.95 |
n, frequency; SD, standard deviation; IQR, inter-quartile range; CDAI, Crohn's disease activity index; RDW, red cell distribution width; Hgb, hemoglobin; WBC, white blood cell count; PLT, platelet count; Anti-TNF-α, anti-tumor necrosis factor-α; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein.
Anemia was defined as hemoglobin <13 g/dL if male gender; or hemoglobin <12 g/dL if female gender.